Search
Levocabastine
go.drugbank.com/drugs/DB01106ApprovedLevocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
Categories: Histamine H1 Antagonists, Non-SedatingVoxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition
Fluocinolone acetonide
go.drugbank.com/drugs/DB00591ApprovedInvestigationalVet approvedFluocinolone acetonide, with the formula 6-alpha, 9-alpha-difluoro-16-alpha, 17 alpha-acetonide, is a corticosteroid that presents a high lipophilicity. It has been used extensively in dermatological preparations and it has also been inv...
Doxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigationalDoxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to cidoxepin. Doxepin commonly produces a 5:...
Categories: Non-Selective Monoamine Reuptake InhibitorsSimeprevir
go.drugbank.com/drugs/DB06290ApprovedWithdrawngenotype 4 patients with or without cirrhosis and is taken with [DB00008] and [DB00811]; this triple therapy allows shortening treatment duration from 48 weeks or longer to 12 or 24 weeks [A19630] depending on
Minocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigational[A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695] … [A190723] Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
Beractant
go.drugbank.com/drugs/DB06761ApprovedIn anticipation of birth, endogenous lung surfactant is produced to lower the surface tension on alveolar surfaces and to stabilize the alveoli against collapse at resting transpulmonary pressures.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243]
Lorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnThis decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer.